Compounds > cochliophilin a
Page last updated: 2024-11-09

cochliophilin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cochliophilin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID927642
CHEMBL ID364596
CHEMBL ID-364596
CHEBI ID174680
SCHEMBL ID971282
MeSH IDM0478863

Synonyms (22)

Synonym
CHEBI:174680
cochliophilin a
9-hydroxy-6-phenyl-[1,3]dioxolo[4,5-g]chromen-8-one
OPREA1_580504
CHEMBL364596
SCHEMBL971282
9-hydroxy-6-phenyl-2h,8h-[1,3]dioxolo[4,5-g]chromen-8-one
9-hydroxy-6-phenyl-8h-1,3-dioxolo[4,5-g][1]benzopyran-8-one
110204-45-0
5-hydroxy-6,7-methylenedioxyflavone
BS-44933
9-hydroxy-6-phenyl-8h-[1,3]dioxolo[4,5-g]chromen-8-one
XC161677
9-oxidanyl-6-phenyl-(1,3)dioxolo(4,5-g)chromen-8-one
9-hydroxy-6-phenyl-8h-1,3-dioxolo(4,5-g)(1)benzopyran-8-one
9jl54rt3qz ,
8h-1,3-dioxolo(4,5-g)(1)benzopyran-8-one, 9-hydroxy-6-phenyl-
chembl-364596
unii-9jl54rt3qz
DTXSID901187957
F74924
AKOS040736336
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
flavonesA member of the class of flavonoid with a 2-aryl-1-benzopyran-4-one (2-arylchromen-4-one) skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID247665Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID246154Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID245888Maximum intracellular vinblastine accumulation of the KB/MDR cells caused by the compound in 1 h2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID247607Inhibitory activity against KB cell line after 72 h of drug exposure2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID237331cLogD was determined2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0210aromatic ether;
nitrile;
polyether;
tertiary amino compound
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		2.0410thiazolidine
5,6,7-trimethoxyflavone
baicalein 5,6,7-trimethyl ether: stimulates fatty acid beta-oxidation; structure in first source. 5,6,7-trimethoxyflavone : A trimethoxyflavone that is the 5,6,7-trimethyl ether derivative of baicalein. It has been isolated from the plant Callicarpa japonica and has been shown to exhibit antiviral activity.		2.0210trimethoxyflavoneanti-HSV-1 agent;
plant metabolite
5-hydroxy-6,7-dimethoxyflavone
mosloflavone: from Ranunculus japonicus; structure in first source		2.0210ether;
flavonoids
baicalein
[no description available]		2.0210trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0210homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
latrunculin b
latrunculin B: 14-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin A; structure given in first source. latrunculin B : A macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica.		2.0410cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
ConditionIndicatedRelationship StrengthStudiesTrials